Clinical trial · Interventional
Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
BrUOG-BR-211B q3week Carboplatin With Weekly Abraxane and Trastuzumab As Neoadjuvant Therapy in Resectable and Unresectable HER2+ (Stage IIa-IIIb) Breast Cancer
NCT00617942CI-TRIAL-00045509completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Q3week carboplatin with weekly abraxane and trastuzumab as neoadjuvant therapy in resectable and unresectable HER2+ (stage IIa-IIIb) breast cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cohort 1 adjuvant | Drug | — | UNRESOLVED |
| Cohort 1 neo-adjuvant | Drug | — | UNRESOLVED |
| Cohort 2 adjuvant | Drug | — | UNRESOLVED |
| Cohort 2 neo-adjuvant | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Neo-adjuvant cohort 1
- interventionNames
- Drug: Cohort 1 neo-adjuvant
- type
- EXPERIMENTAL
- label
- Neo-adjuvant cohort 2
- interventionNames
- Drug: Cohort 2 neo-adjuvant
- type
- EXPERIMENTAL
- label
- Adjuvant cohort 1
- interventionNames
- Drug: Cohort 1 adjuvant
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically documented adenocarcinoma of the breast * ANC \> 1000 cells * Female; age \> 18; Zubrod PS 0-1 * Platelets \> 100,000 * Stage IIA-IIIB disease * Total bilirubin \< or = ULN * No evidence of metastatic disease Not pregnant or lactating * No prior systemic therapy for this breast cancer * Serum Creatinine \< 1.5 mg/dl or Creat Cl \> 30 ml/min * Serum ALT \< 2.5 x ULN * ER, PR and HER2 status required * LVEF (MUGA/echo)WNL * No baseline \> 2 neuropathy * Hemoglobin \> 9.0 gm/dl * HER2+, defined by IHC 3+ or FISH ratio \> 2.0
References
Publications (1)
- DERIVEDCheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL. Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab. BMC Cancer. 2014 May 8;14:326. doi: 10.1186/1471-2407-14-326. PMID 24885187